For the Inventor, By the Inventor

Enter assignee name

Elf Sanofi

USPTO Granted Patents = 53

Trademarks = 1

Forward Citations = 552

Loading Chart...

Loading Chart...

130 inventors (with patents filed for the assignee):

Jean Gubin (6 out of 19 patents)

Umberto Guzzi (5 out of 43 patents)

Vincenzo Proietto (5 out of 47 patents)

4. Dino Nisato (4 out of 41 patents)

5. Xavier Emonds-Alt (4 out of 46 patents)

6. Jean-Claude Breliere (4 out of 8 patents)

7. Danielle Gully (4 out of 28 patents)

8. Tiziano Croci (3 out of 25 patents)

9. Alain Badorc (3 out of 16 patents)

10. Patrick Gueule (3 out of 32 patents)

11. Claude Bernhart (3 out of 12 patents)

12. Robert Boigegrain (3 out of 37 patents)

13. Didier Van Broeck (3 out of 40 patents)

14. Dominique Olliero (3 out of 16 patents)

15. Alberto Bianchetti (3 out of 19 patents)

Core Competencies:

Quaternary Ammonium Salts

Indolizine Derivatives

Polycyclic Amine Compounds

Pharmaceutical Activity

Heterocyclic Derivatives

N-Alkylenepiperidino Compounds

Enzyme Production

Oligosaccharides

Dinitrogen Heterocycles

Aromatic Acid Intermediates

Angiogenesis Inhibitors

Transcutaneous Administration

53 patents: Sort by Forward Citations

1. 5773620 - Quaternary ammonium salts of aromatic amine compounds, their preparation (1998-06-30),

2. 5770735 - Polycyclic amine compounds and their enantiomers, their method of (1998-06-23),

3. 5739340 - Indolizine derivatives with pharmaceutical activity (1998-04-14),

4. 5674881 - Quaternary ammonium salts of aromatic amine compounds, their preparation (1997-10-07),

5. 5604245 - Use of 4-amino-1-(2-pyridyl)piperidines for the preparation of a (1997-02-18),

6. 5576328 - Method for the secondary prevention of ischemic events (1996-11-19),

7. 5567827 - 4-Hydroxyphenylthio derivatives, their preparation and their use for the (1996-10-22),

8. 5534530 - 5-acylamino-1,2,4-thiadiazoles, their preparation and pharmaceutical (1996-07-09),

9. 5514659 - 3-deoxy oligosaccharides and pharmaceutical compositions containing them (1996-05-07),

10. 5508431 - 4-hydroxyphenylthio derivatives, their preparation and their use for the (1996-04-16),

11. 5506258 - Compounds bearing sulphamoyl and amidino radicals, their preparation (1996-04-09),

12. 5482844 - Enzyme intended for the fragmentation of N-acetylheparosan, production (1996-01-09),

13. 5477001 - Recombinant DNA coding for a novel protein having .beta.-1,3-glucanase (1995-12-19),

14. 5468750 - Heterocycle-coupled substituted pyrrolo[3,2-c]pyridin-2-carboxylic acids (1995-11-21),

15. 5464847 - Branched alkylamino derivatives of thiazole, processes for preparing (1995-11-07),

Company Overview

Elf Sanofi, headquartered in Paris, specializes in pharmaceutical chemistry with a focus on innovative compounds and therapeutic solutions. The company is engaged in the development and manufacturing of a diverse range of chemical entities, including quaternary ammonium salts, indolizine derivatives, and polycyclic amine compounds. Its research encompasses various core technology topics such as enzyme production and oligosaccharides, positioning Elf Sanofi as a key player in advancing pharmaceutical applications and enhancing healthcare outcomes.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

53 Patents

#125 in Paris

#455 in France

#13,348 in the World

Elf Sanofi

Forward Citations = 552

130 inventors:

Jean Gubin (6 out of 19 patents)

Umberto Guzzi (5 out of 43 patents)

Vincenzo Proietto (5 out of 47 patents)

4. Dino Nisato (4 out of 41 patents)

5. Xavier Emonds-Alt (4 out of 46 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Elf Sanofi. Retrieved from https://idiyas.com/company/elf-sanofi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…